Mesoblast (NASDAQ:MESO) Downgraded by StockNews.com to “Sell”

StockNews.com cut shares of Mesoblast (NASDAQ:MESO) from a hold rating to a sell rating in a report issued on Wednesday.

Several other equities analysts have also recently weighed in on the stock. Jefferies Financial Group upgraded shares of Mesoblast from a hold rating to a buy rating in a research report on Thursday, August 29th. Cantor Fitzgerald reiterated an overweight rating on shares of Mesoblast in a research report on Thursday, August 29th. Finally, Piper Sandler upgraded shares of Mesoblast from a neutral rating to an overweight rating and lifted their price objective for the stock from $4.00 to $11.00 in a research report on Tuesday, July 23rd.

Mesoblast Stock Performance

NASDAQ MESO opened at $6.55 on Wednesday. Mesoblast has a twelve month low of $1.61 and a twelve month high of $8.66. The stock has a market cap of $747.87 million, a price-to-earnings ratio of -5.85 and a beta of 3.48. The firm’s 50 day moving average price is $6.85 and its two-hundred day moving average price is $5.94.

Institutional Investors Weigh In On Mesoblast

Institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC boosted its stake in shares of Mesoblast by 50.1% during the 2nd quarter. GAMMA Investing LLC now owns 4,981 shares of the company’s stock valued at $34,000 after buying an additional 1,663 shares during the period. Chapin Davis Inc. boosted its stake in shares of Mesoblast by 50.0% during the 2nd quarter. Chapin Davis Inc. now owns 15,000 shares of the company’s stock valued at $102,000 after buying an additional 5,000 shares during the period. Pine Valley Investments Ltd Liability Co acquired a new stake in shares of Mesoblast during the 2nd quarter valued at $80,000. Marshall Wace LLP acquired a new stake in shares of Mesoblast in the 2nd quarter valued at $562,000. Finally, XTX Topco Ltd acquired a new stake in shares of Mesoblast in the 2nd quarter valued at $103,000. Institutional investors and hedge funds own 1.43% of the company’s stock.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.